Loading...
http://jcps.bjmu.edu.cn

Table of Content

    31 March 2025, Volume 34 Issue 3
    Original articles
    Study on chemical constituents from ethanol extract of Cyclocarya paliurus
    Hailong Xu, Jiao Yang, Tianxia Wang, Gaigai Deng, Youbo Zhang
    2025, 34(3):  195-209.  DOI: 10.5246/jcps.2025.03.015
    Asbtract ( 12 )   HTML ( 11)  
    Figures and Tables | References | Related Articles | Metrics

    The aim of this study is to isolate and identify the chemical compounds in ethanol extract of Cyclocarya paliurus. Some purification and analysis techniques like silica gel, D101-macroporous adsorptive resins, and Sephadex LH-20 column chromatographies as well as high-performance liquid chromatography were used to isolate and analyze the compounds from ethanol extract of Cyclocarya paliurus. The structures of these constituents were identified by spectroscopic techniques such as nuclear magnetic resonance and high-resolution mass spectrometries. Twenty-eight compounds, including flavonoids and their glycoside, carbohydrate, coumarin and organic acid, were isolated from ethyl acetate and n-butanol fractions in ethanol extract of Cyclocarya paliurus, and they were identified as kaempferol (1), coumestrol (2), kaempferol 3-O-β-D-glucoside (3), methyl caffeoylquinic acid (4), coptichic aldehyde (5), schizandriside (6), kaempferol 3-O-α-L-rhamnoside (7), 3-caffeoylquinic acid ethyl ester (8), quercetin (9), luteolin (10), protocatechuic acid (11), kaempferol-3-O-α-L-furan arabinose (12), trans-p-hydroxy-cinnamic acid (13), α-D-glucopyranosido-β-D-fructofuranoside, sucrose (14), peucedanol (15), chlorogenic acid (16), pyridoxine (17), quercetin-3-O-β-D-glucuronide (18), kaempferol-3-O-β-D-glucuronide (19), isoquercitrin (20), mururin A (21), citroside A (22), benzyl-6-O-α-L-arabinofuranosyl-β-D-glucopyranoside (23), (+)-(6S,9R)-9-O-β-D-glucopyranosyl-6-hydroxy-3-O-α-ionol (24), myricetin-3-O-β-D-glucopyranoside (25), (4R)-4-(3-Oxo-1-buten-1-ylidene)-3α,5,5-trimethylcyclohexane-1α,3β-diol (26), quercetin-3-O-α-L-rhamnopyranosyl (27) and 3,5-O-dicaffeoylquinic acid (28). Compounds 2, 5, 6, 15, 21, 22, 23, 24, 26 and 28 were isolated from Cyclocarya paliurus for the first time.

    Synthesis and functional evaluation of low-molecular-weight dextran sulfate as an inhibitor of TGF-β1-induced epithelial-to-mesenchymal transition in A549 cells
    Guohao Song, Linbo Fu, Yidian Mo, Tongtong Geng, Ximin Lv, Xiangbao Meng, Heng Wang, Zhongtang Li, Zhongjun Li
    2025, 34(3):  210-222.  DOI: 10.5246/jcps.2025.03.016
    Asbtract ( 7 )   HTML ( 3)  
    Figures and Tables | References | Related Articles | Metrics

    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by excessive fibrotic remodeling, for which effective therapeutic options remain severely limited. Among the pathogenic mechanisms implicated in IPF, epithelial-to-mesenchymal transition (EMT) is recognized as a pivotal driver of fibroblast activation and extracellular matrix deposition. In this study, we aimed to develop low-molecular-weight dextran sulfate sodium (LMW-DSS) derivatives and assess their capacity to interfere with EMT, thereby offering novel therapeutic avenues for IPF management. Starting with dextran (2 kDa) as a precursor, we successfully synthesized two sulfated derivatives, DSS-LS and DSS-HS, via distinct sulfonation processes. Using a TGF-β1-stimulated A549 alveolar epithelial cell model, we demonstrated that LMW-DSS compounds exhibited no cytotoxicity, as validated by CCK-8 viability assays. Importantly, Transwell migration assays revealed that LMW-DSS markedly attenuated TGF-β1-induced A549 cell migration, indicating a potent anti-fibrotic effect. Moreover, qPCR and Western blotting analyses confirmed that LMW-DSS significantly suppressed the expression and secretion of key pro-fibrotic mediators, including TGF-β1 and VEGF-A, and downregulated critical EMT-associated markers such as Snail and vimentin. Notably, reduced α-SMA expression following LMW-DSS treatment further substantiated its role in hindering EMT progression. Collectively, these findings highlighted the capacity of LMW-DSS to effectively impede EMT and fibrotic processes, thereby delaying the progression of pulmonary fibrosis. This work not only underscored the therapeutic potential of LMW-DSS in IPF but also provided compelling experimental evidence to support its development as a promising anti-fibrotic agent for clinical application.

    Analysis of 979 cases of adverse drug reactions induced by antineoplastic drugs
    Xingnong Xu, Doudou He, Lei Ma
    2025, 34(3):  223-231.  DOI: 10.5246/jcps.2025.03.017
    Asbtract ( 7 )   HTML ( 2)  
    Figures and Tables | References | Related Articles | Metrics

    The aim of this study is to evaluate the characteristics and patterns of adverse drug reactions (ADRs) associated with antineoplastic drugs and provide insights for safer chemotherapy practices. Based on 979 ADR cases reported in our hospital from January 1, 2022, to December 31, 2023, an analysis was conducted. Statistical analysis of the data revealed that 72.73% of these ADR incidents occurred in a hospital setting. The incidence of ADRs was higher in female patients compared to males, with the majority of cases (59.14%) observed in individuals aged 51–70 years. Intravenous administration was the predominant route linked to ADRs, accounting for 69.66% of the cases. Serious ADRs represented 9.30% of the total, including one instance where symptoms did not improve despite drug discontinuation or treatment. Cytotoxic antineoplastic drugs were responsible for 97.85% of all ADRs, with oxaliplatin being the most frequently implicated agent (19.82%). Gastrointestinal system involvement was the most common ADR manifestation, observed in 60.79% of cases. These findings underscored the necessity of enhanced monitoring for ADRs associated with cytotoxic antineoplastic drugs, particularly platinum-based agents. Comprehensive risk assessments and tailored treatment plans should be implemented during chemotherapy to minimize the occurrence of ADRs and safeguard patient safety.

    Bibliometric analysis of PCSK9 inhibitors for cardiovascular disease management based on Web of Science
    Yu Wang, Xiaojing Lu, Xiangfeng Yue, Linwei Kan, Shuzhang Du
    2025, 34(3):  232-250.  DOI: 10.5246/jcps.2025.03.018
    Asbtract ( 2 )   HTML ( 3)  
    Figures and Tables | References | Related Articles | Metrics

    o comprehensively analyze the current research landscape and emerging trends in the application of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treating cardiovascular diseases, a bibliometric analysis was conducted. Relevant English-language literature on PCSK9 inhibitors in cardiovascular treatment, published between January 1, 2013, and December 31, 2023, was retrieved from the Web of Science core collection database. Utilizing tools such as VOSviewer 1.6.20, CiteSpace 6.2.R6, and Excel 2021, the study examined key features of the literature, including annual publication trends, contributing countries/regions, institutions, authors, journals, and key research themes. The analysis identified a total of 1383 articles, revealing a general upward trend in annual publication output. Research in this field has been conducted by 78 countries/regions, with the United States leading in the number of publications (563 articles). The United States also demonstrates strong collaborative networks with other leading countries, including the United Kingdom, Canada, the Netherlands, Australia, Italy, Germany, and Switzerland. In terms of institutional contributions, 2379 institutions have published relevant studies, with Amgen Inc. producing the most publications (n = 70). Among individual contributors, Professor Giugliano from the Thrombolysis in Myocardial Infarction (TIMI) Study Group at Brigham and Women’s Hospital and Harvard Medical School is the most prolific author, with 37 publications. Meanwhile, Professor Sabatine, also from the TIMI Study Group, holds the highest number of co-citations, underscoring his influence in the field. The analysis also identified 436 journals publishing research on PCSK9 inhibitors, with the Journal of Clinical Lipidology being the most productive (n = 54). However, the New England Journal of Medicine is noted as the journal with the highest co-citation count, indicating its significant impact on this research area. Research hotspots have focused on the efficacy and safety of PCSK9 inhibitors, alongside the clinical application of conventional lipid-lowering therapies such as statins and ezetimibe. Notably, the development of monoclonal antibodies and siRNA-based therapies targeting PCSK9 has gained considerable attention over the past decade due to their superior ability to lower low-density lipoprotein cholesterol (LDL-C). The effectiveness and long-term safety profiles of these novel agents are of growing interest, prompting updates to lipid management guidelines and offering new perspectives for the prevention and treatment of cardiovascular diseases.

    Elucidating the mechanism of Kuwanon G in treating diabetic encephalopathy through network pharmacology: A comprehensive study
    Yuqian Zhang, Haiying Niu, Xiaowei Zhang, Weiwei Xie, Kaiyue Zhang, Lantong Zhang, Yiran Jin
    2025, 34(3):  251-259.  DOI: 10.5246/jcps.2025.03.019
    Asbtract ( 2 )   HTML ( 3)  
    Figures and Tables | References | Related Articles | Metrics

    The present study employed network pharmacology to elucidate the molecular mechanism underlying the therapeutic effects of kuwanon G in diabetic encephalopathy. Utilizing the Pharmmapper databases, we identified potential targets associated with kuwanon G. Simultaneously, targets related to diabetic encephalopathy were screened. The VENNY software facilitated the identification of 34 common target genes, forming the basis for constructing a protein-protein interaction network map via the STRING database. GO enrichment and KEGG pathway analyses were conducted using the David database, with Cytoscape software employed to pinpoint key target genes. Results revealed 101 potential targets for kuwanon G and 1058 for diabetic encephalopathy, with an overlap of 34 target genes. Notably, GSK3B, CASP3, MAKP14, ESR1, and PPARG emerged as pivotal genes in the therapeutic action of kuwanon G against diabetic encephalopathy. Pathway analysis of these key genes indicated that kuwanon G exerted its therapeutic effects through modulating pathways associated with lipid and atherosclerosis, fluid shear stress and atherosclerosis, IL-17 signaling, and the AGE-RAGE signaling pathway. This study offered valuable insights into the potential molecular mechanisms of kuwanon G in treating diabetic encephalopathy, presenting a novel framework for future research in this domain.

    Drug administration and clinical pharmacy column
    Advancing pediatric drug development in China: implementation of the national priority R&D encouragement list
    Weimiao Li, Jing Chen, Luwen Shi
    2025, 34(3):  260-268.  DOI: 10.5246/jcps.2025.03.020
    Asbtract ( 2 )   HTML ( 3)  
    Figures and Tables | References | Related Articles | Metrics

    Access to medicines for children is a critical global issue that demands urgent attention. In China, the need is particularly acute due to its large pediatric population and corresponding clinical demand. This study aimed to analyze the characteristics of drugs included in the Encouraging R&D and Declaring the Children Medicine Lists issued by the Chinese government from 2016 to 2023, and to assess the accessibility and challenges associated with these priority medicines. Data were collected from the official websites of the Health, Industry, and Drug Regulatory Departments of the People’s Republic of China. By organizing information on 129 drugs included in all the lists, a systematic analysis was conducted to evaluate the effectiveness of China’s pediatric medication policies. The 129 listed medications featured a variety of child-friendly formulations, including injections (28%), solutions (20%), suspensions (15%), topical preparations (6%), sprays (3%), and other forms. These drugs primarily target common childhood illnesses, such as diseases affecting the nervous system, cardiovascular system, tumors, infections, digestive system, and endocrine system, which collectively account for 73% of the total. In contrast, treatments for rare diseases represented only 9% of the listed medications. Among these drugs, 22 (17%) were previously unavailable on the market but have since been approved for sale, with 19 (86%) of them included in national or local reimbursement drug lists. However, half of the drugs (64, 50%) have yet to be submitted for any investigational new drug applications, indicating areas where progress remains slow. While the policy has successfully incentivized innovation in pediatric drug development, leading to the introduction of novel therapies and new dosage forms for rare diseases and unmet medical needs in children, significant challenges persist. The findings highlighted ongoing gaps in pediatric drug development and accessibility. Continuous monitoring and evaluation are crucial to sustaining progress, addressing obstacles, and ensuring equitable access to essential pediatric medicines.

    Synthesis and in vitro/in vivo assessment of sustained-release oral oseltamivir phosphate suspension
    Yuanrong Xin, Yutian Dou, Xiaolin Chen, Yingshu Feng, Xuesheng Liu, Caleb Kesse Firempong, Dan Yang, Hongfei Liu, Haibing He
    2025, 34(3):  269-283.  DOI: 10.5246/jcps.2025.03.021
    Asbtract ( 0 )   HTML ( 2)  
    Figures and Tables | References | Related Articles | Metrics

    Oseltamivir phosphate (OP), renowned as one of the most effective drugs for influenza treatment, encounters several challenges, including poor stability, difficulty in swallowing, and a bitter taste, thereby limiting its compliance, particularly among children. Consequently, this study aimed to devise a novel sustained-release suspension of OP employing an ion exchange resin as a carrier to address these challenges. The OP-drug resin complex (OP-DRC) was synthesized utilizing ion exchange technology, while OP-coated microcapsules (OP-CM) were fabricated via the emulsion-evaporation method. The optimization of the formulation process for the OP sustained-release suspension was achieved through a combination of single-factor experimentation and orthogonal experimental design. Furthermore, the drug release kinetics and pharmacokinetic properties of the sustained-release suspension were thoroughly evaluated both in vitro and in vivo. Scanning electron microscopy (SEM), X-ray diffraction (XRD), and attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-FTIR) analyses confirmed the formation of drug-resin complexes via ionic bonding. The in vitro cumulative release rates were found to be 16% (1 h), 53% (6 h), and 84% (24 h), respectively. Notably, the self-made sustained-release suspension exhibited an extended half-life (21.518 h), delayed time to peak concentration (Tmax) (6 h), and reduced maximum plasma concentration (Cmax) (0.397 μg/mL) in comparison to commercial granules (half-life = 8.466 h; Tmax = 2 h; Cmax = 0.631 μg/mL). Additionally, the area under the curve (AUC) indicated that the bioavailability of the self-made OP suspension surpassed that of the commercial OP granules by 101%. These findings underscored the successful development of an oral OP sustained-release suspension characterized by stability, tastelessness, ease of swallowing, convenient administration, and sustained-release properties, thereby potentially enhancing drug compliance among children.